Paromomycin as a Treatment for Cryptosporidiosis

Cryptosporidiosis, caused by the protozoan parasite Cryptosporidium, poses a significant challenge to veterinarians. The disease is self-limiting in the immune competent host but poses a significant threat in immune deficient individuals. Also, oocysts are highly resistant to environmental stress and many disinfectants, so hygienic measures alone are generally not sufficient to reliably eliminate oocysts from animal housing facilities and thus to avoid infection (Shahiduzzaman, 2012). Paromomycin, an aminoglycoside antibiotic, has emerged as a promising option in combating cryptosporidiosis. 

Unlike other antibiotics, paromomycin exhibits minimal systemic absorption, making it an ideal candidate for gastrointestinal infections like cryptosporidiosis. Its mechanism of action involves inhibiting protein synthesis in the parasite, effectively halting its replication and spread within the host’s intestines. 

In veterinary medicine, paromomycin has shown efficacy in treating cryptosporidiosis across various animal species, including calves, lambs, and foals. Its safety profile and low risk of resistance development make it particularly appealing for use in young, immunocompromised, or debilitated animals. 

Pharmacy Solutions has made various strengths of dose-specific, flavored suspensions to treat veterinary needs, particularly in zoological settings. When incorporating paromomycin into treatment regimens, veterinarians must consider dosage, duration, and potential adverse effects. Close monitoring of patients is essential to ensure therapeutic success while minimizing any unwanted reactions.

(Shahiduzzaman, M., & Daugschies, A., 2012). Therapy and prevention of cryptosporidiosis in animals. Veterinary Parasitology, 188(3–4), 203–214. https://doi.org/10.1016/j.vetpar.2012.03.052